Pediatric Nephrology

, Volume 21, Issue 9, pp 1257–1265 | Cite as

Urine proteomic profiling of pediatric nephrotic syndrome

  • Mona Khurana
  • Avram Z. Traum
  • Manuel Aivado
  • Meghan P. Wells
  • Manuel Guerrero
  • Franck Grall
  • Towia A. Libermann
  • Asher D. Schachter
Original Article


The prognosis of pediatric nephrotic syndrome (NS) correlates with the responsiveness to glucocorticoid therapy. Steroid-resistant NS (SRNS) patients progress to end-stage renal disease, while steroid-sensitive NS (SSNS) and steroid-dependent (SDNS) patients do not. We have performed proteomic profiling of urine samples from a cross section of pediatric and adolescent subjects with SSNS, SRNS, and orthostatic proteinuria (OP) to identify urinary biomarkers of steroid resistance. We performed surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS) on urine from 19 subjects with SSNS/SDNS in remission, 14 with SSNS/SDNS in relapse, 5 with SRNS in relapse, and 6 with OP. Genetic algorithm search of principal component space revealed a group of five peaks distinguishing SRNS subjects, with mass/charge (m/z) values of 3,917.07, 4,155.53, 6,329.68, 7,036.96, and 11,117.4. Our analyses identified the peak at m/z 11,117.4 with an accuracy of 95% for classifying SRNS. Multidimensional protein fractionation and mass spectrometric analysis of SRNS urine samples combined with immunodepletion identified the 11,117.4 protein as β2-microglobulin (B2M). Using an unbiased protein profiling approach, we have validated previously reported findings of B2M as a biomarker associated with SRNS. Prospective studies are warranted to establish additional biomarkers that would be predictive of SRNS.


Focal segmental glomerulosclerosis Nephrotic syndrome Steroid resistance Urine proteomics β2-Microglobulin 





Focal segmental glomerulosclerosis


Genetic algorithm


High-performance reverse phase


Matrix-assisted laser desorption/ionization


Mass spectrometry




Nephrotic syndrome


Orthostatic proteinuria


Principal component analysis


Steroid dependent


Steroid-dependent nephrotic syndrome


Surface-enhanced laser desorption/ionization


Steroid resistant


Steroid-resistant nephrotic syndrome


Steroid sensitive


Steroid-sensitive nephrotic syndrome


Time of flight



This work was supported in part by NIH Training Grant T32 DK 007726 (MK and AZT), and by NIH grant K23 RR 16080 (ADS). Parts of this work were presented (abstract TH-PO160) at the American Society of Nephrology Renal Week 2005, Philadelphia, PA.


  1. 1.
    Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242–1249PubMedCrossRefGoogle Scholar
  2. 2.
    Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM (2005) High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 68:1275–1281PubMedCrossRefGoogle Scholar
  3. 3.
    Schlesinger ER, Sultz HA, Mosher WE, Feldman JG (1968) The nephrotic syndrome. Its incidence and implications for the community. Am J Dis Child 116:623–632PubMedGoogle Scholar
  4. 4.
    Srivastava T, Simon SD, Alon US (1999) High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13:13–18PubMedCrossRefGoogle Scholar
  5. 5.
    (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561–564Google Scholar
  6. 6.
    (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765–771Google Scholar
  7. 7.
    Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ (1989) Nephrotic syndrome: from toddlers to twenties. Lancet 1:255–259PubMedCrossRefGoogle Scholar
  8. 8.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM, Jr. (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMedGoogle Scholar
  9. 9.
    Seikaly M, Ho PL, Emmett L, Tejani A (2001) The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 5:215–231PubMedCrossRefGoogle Scholar
  10. 10.
    Tejani A, Stablein DH (1992) Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 2:S258–263PubMedGoogle Scholar
  11. 11.
    Baum MA (2004) Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 8:329–333PubMedCrossRefGoogle Scholar
  12. 12.
    Schachter AD, Harmon WE (2001) Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 5:406–409PubMedCrossRefGoogle Scholar
  13. 13.
    Andreoli SP (2004) Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children. Adv Ren Replace Ther 11:105–109PubMedCrossRefGoogle Scholar
  14. 14.
    Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford R, Portman R, Verani R (1999) Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 55:1885–1890PubMedCrossRefGoogle Scholar
  15. 15.
    Rennke HG (1994) How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 45:S58–63PubMedCrossRefGoogle Scholar
  16. 16.
    Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577PubMedCrossRefGoogle Scholar
  17. 17.
    Petricoin EF, 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA (2002) Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576–1578PubMedGoogle Scholar
  18. 18.
    Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW (2003) Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3:2310–2316PubMedCrossRefGoogle Scholar
  19. 19.
    Huber M, Bahr I, Kratzschmar JR, Becker A, Muller EC, Donner P, Pohlenz HD, Schneider MR, Sommer A (2004) Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol Cell Proteomics 3:43–55PubMedGoogle Scholar
  20. 20.
    Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB (2005) Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16:2967–2975PubMedCrossRefGoogle Scholar
  21. 21.
    Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65:323–332PubMedCrossRefGoogle Scholar
  22. 22.
    Traum AZ, Wells MP, Aivado M, Libermann TA, Ramoni MF, Schachter AD (2006) SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 6:1676–1680PubMedCrossRefGoogle Scholar
  23. 23.
    O’Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S, Mya M, Hu R, Momin J, Eng EW, Hampel DJ, Hartman B, Kretzler M, Delaney V, Goligorsky MS (2004) Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 15:3240–3248PubMedCrossRefGoogle Scholar
  24. 24.
    Nguyen MT, Ross GF, Dent CL, Devarajan P (2005) Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 25:318–326PubMedCrossRefGoogle Scholar
  25. 25.
    Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H (2005) Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67:2313–2320PubMedCrossRefGoogle Scholar
  26. 26.
    Winston PH (1992) Learning by simulating evolution. In: Katz B (ed) Artificial intelligence. Addison-Wesley, Reading, MA, pp 505–528Google Scholar
  27. 27.
    R Development Core Team (2005) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, AustriaGoogle Scholar
  28. 28.
    Arbus GS, Poucell S, Bacheyie GS, Baumal R (1982) Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. J Pediatr 101:40–45PubMedCrossRefGoogle Scholar
  29. 29.
    Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ (1988) Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 113:996–1001PubMedCrossRefGoogle Scholar
  30. 30.
    Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA, Wetzels JF (2005) Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 16:169–174PubMedCrossRefGoogle Scholar
  31. 31.
    Caliskan S, Hacibekiroglu M, Sever L, Ozbay G, Arisoy N (1996) Urinary N-acetyl-beta-D-glucosaminidase and beta 2-microglobulin excretion in primary nephrotic children. Nephron 74:401–404PubMedGoogle Scholar
  32. 32.
    Fede C, Conti G, Chimenz R, Ricca M (1999) N-acetyl-beta-D-glucosaminidase and beta2-microglobulin: prognostic markers in idiopathic nephrotic syndrome. J Nephrol 12:51–55PubMedGoogle Scholar
  33. 33.
    Ramjee G, Coovadia HM, Adhikari M (1994) Sodium dodecyl sulphate polyacrylamide gel electrophoresis of urinary proteins in steroid-responsive and steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 8:653–656PubMedCrossRefGoogle Scholar
  34. 34.
    Reichert LJ, Koene RA, Wetzels JF (1995) Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 6:1666–1669PubMedGoogle Scholar
  35. 35.
    Reichert LJ, Koene RA, Wetzels JF (1999) Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrol Dial Transplant 14:91–97PubMedCrossRefGoogle Scholar
  36. 36.
    Robeva R, Heslan JM, Branellec A, Laurent J, Lagrue G (1988) Enhanced beta 2-microglobulin levels in lymphocyte culture supernatants from patients with idiopathic nephrotic syndrome: inhibition of lymphocyte activation by cyclosporine. Clin Nephrol 30:211–215PubMedGoogle Scholar
  37. 37.
    Sesso R, Santos AP, Nishida SK, Klag MJ, Carvalhaes JT, Ajzen H, Ramos OL, Pereira AB (1992) Prediction of steroid responsiveness in the idiopathic nephrotic syndrome using urinary retinol-binding protein and beta-2-microglobulin. Ann Intern Med 116:905–909PubMedGoogle Scholar
  38. 38.
    Thielemans N, Lauwerys R, Bernard A (1994) Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 66:453–458PubMedGoogle Scholar
  39. 39.
    Valles P, Peralta M, Carrizo L, Martin L, Principi I, Gonzalez A, Manucha W (2000) Follow-up of steroid-resistant nephrotic syndrome: tubular proteinuria and enzymuria. Pediatr Nephrol 15:252–258PubMedCrossRefGoogle Scholar
  40. 40.
    Wetzels JF, Sluiter HE, Hoitsma AJ, van Munster PJ, Koene RA (1988) Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int 33:1169–1174PubMedCrossRefGoogle Scholar
  41. 41.
    Bokenkamp A, Grabensee A, Stoffel-Wagner B, Hasan C, Henne T, Offner G, Lentze MJ (2002) The beta2-microglobulin/cystatin C ratio-a potential marker of post-transplant lymphoproliferative disease. Clin Nephrol 58:417–422PubMedGoogle Scholar
  42. 42.
    Karlsson FA, Wibell L, Evrin PE (1980) beta 2-Microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl 154:27–37PubMedGoogle Scholar
  43. 43.
    Sasaki TM, Pirsch JD, D’Alessandro AM, Knechtle SJ, Kalayoglu M, Hafez GR, Sollinger HW (1997) Increased beta 2-microglobulin (B2M) is useful in the detection of post-transplant lymphoproliferative disease (PTLD). Clin Transplant 11:29–33PubMedGoogle Scholar
  44. 44.
    Roxe DM, Siddiqui F, Santhanam S, del Greco F, Wolf J (1981) Rationale and application of beta-2-microglobulin measurements to detect acute transplant rejection. Nephron 27:260–264PubMedGoogle Scholar
  45. 45.
    Schardijn GH, Statius van Eps LW (1987) Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int 32:635–641PubMedCrossRefGoogle Scholar
  46. 46.
    Woo KT, Lee EJ, Lau YK, Lim CH (1985) Beta-2-microglobulin in the assessment of renal function of the transplanted kidney. Nephron 39:223–227PubMedCrossRefGoogle Scholar
  47. 47.
    Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim LY, Shipulina NV, Chan DW, Semmes OJ, Eastwood Leung HC (2005) Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5:3467–3474PubMedCrossRefGoogle Scholar
  48. 48.
    Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L (2005) Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51:102–112PubMedCrossRefGoogle Scholar
  49. 49.
    Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, Nickerson P (2005) Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 5:729–738PubMedCrossRefGoogle Scholar
  50. 50.
    Schachter AD (2004) The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity. Pediatr Transplant 8:344–348PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Mona Khurana
    • 1
    • 5
  • Avram Z. Traum
    • 1
    • 5
  • Manuel Aivado
    • 2
    • 3
    • 5
  • Meghan P. Wells
    • 2
    • 3
  • Manuel Guerrero
    • 2
    • 3
  • Franck Grall
    • 2
    • 3
    • 5
  • Towia A. Libermann
    • 2
    • 3
    • 5
  • Asher D. Schachter
    • 1
    • 4
    • 5
  1. 1.Department of PediatricsDivision of Nephrology, Children’s Hospital BostonBostonUSA
  2. 2.Beth Israel Deaconess Medical CenterBostonUSA
  3. 3.Dana Farber/Harvard Cancer Center Proteomics CoreBostonUSA
  4. 4.Children’s Hospital Informatics Program at Harvard-MIT Division of Health Sciences and TechnologyBostonUSA
  5. 5.Harvard Medical SchoolBostonUSA

Personalised recommendations